{"paper_id":"39e37dbd-0e5f-4abc-aadc-71fe31683f83","body_text":"Review began\n 10/14/2026 \nReview ended\n 11/01/2026 \nPublished\n 11/09/2026\n© Copyright \n2026\nGupte et al. This is an open access article\ndistributed under the terms of the Creative\nCommons Attribution License CC-BY 4.0.,\nwhich permits unrestricted use, distribution,\nand reproduction in any medium, provided\nthe original author and source are credited.\nDOI:\n 10.7759/cureus.119395\nElagolix for Endometriosis-Associated Pain: A\nNarrative Review and Indian Expert Consensus\nSanjay Gupte \n, \nRamanidevi T \n, \nK D. Nayyar \n, \nPM Gopinath \n, \nRooma Sinha \n, \nJeyarani Kamaraj \n,\nJayanthi Reddy \n, \nMala Raj \n, \nGirija Wagh \n, \nParag Biniwale \n, \nSushma Deshmukh \n, \nChaitanya Ganpule \n,\nSachin Kulkarni \n, \nShivani S. Gour \n, \nOnkar C. Swami \n, \nKamal Kumar \n, \nNeeraj Kumar \n1.\n Obstetrics and Gynecology, Gupte Hospital, Pune, IND \n2.\n Obstetrics and Gynecology, Ramakrishna Medical Centre\nLLP, Tiruchirappalli, IND \n3.\n Obstetrics and Gynecology, Akanksha IVF Centre, Mata Chanan Devi Hospital, New Delhi,\nIND \n4.\n Reproductive Medicine, Kauvery Hospital, Chennai, IND \n5.\n Obstetrics and Gynecology, Apollo Health City,\nHyderabad, IND \n6.\n Obstetrics and Gynecology, Aakash Fertility Centre and Hospital, Chennai, IND \n7.\n Obstetrics and\nGynecology, JJ Hospital, Hyderabad, IND \n8.\n Obstetrics and Gynecology, FIRM Hospitals, Chennai, IND \n9.\n Obstetrics and\nGynecology, Bharati Vidyapeeth, Pune, IND \n10.\n Obstetrics and Gynecology, Biniwale Clinic, Pune, IND \n11.\n Obstetrics\nand Gynecology, Central India Test Tube Centre, Nagpur, IND \n12.\n Obstetrics and Gynecology, Yash IVF Hospital, Pune,\nIND \n13.\n Obstetrics and Gynecology, Pristine Women's Hospital, Kolhapur, IND \n14.\n Obstetrics and Gynecology, SCI\nHealthcare and SCI IVF Hospital, Delhi, IND \n15.\n Medical Services, Alembic Pharmaceuticals Ltd., Mumbai, IND\nCorresponding author: \nKamal Kumar, \nkamal.kumar@alembic.co.in\nAbstract\nEndometriosis is a chronic, estrogen‑dependent disorder that places a considerable physical, psychosocial,\nand economic burden on women of reproductive age in India. Diagnostic delays, variation in clinical\npresentation, and uncertainty regarding the optimal use of newer oral therapies continue to complicate\nroutine care. Elagolix, an oral gonadotropin‑releasing hormone (GnRH) receptor antagonist, has recently\nbeen approved in India for the treatment of moderate to severe endometriosis‑associated pain; however,\nguidance tailored to Indian clinical practice has been lacking.\nTo address this unmet need, an expert consensus was developed to provide practical recommendations for\nthe evaluation and management of endometriosis, with a specific focus on the positioning of elagolix in\nwomen who are not actively pursuing fertility. A structured modified Delphi approach was used, beginning\nwith statement development by a steering committee, followed by regional expert panel discussions across\nIndia and anonymous validation using a 5‑point Likert scale. Consensus was obtained with at least 75%\nagreement among participating experts.\nEleven consensus statements were finalized, addressing early recognition, diagnostic strategies, empirical\nmedical treatment, and the appropriate selection, dosing, and monitoring of elagolix. The panel emphasized\nearly diagnosis, skilled transvaginal ultrasonography as first‑line imaging, and medical therapy as the\nfoundation of pain management in non‑fertility‑seeking women. Elagolix was recognized as an effective\noral option for selected patients, particularly those with inadequate response or intolerance to first‑line\nhormonal therapies, when used with individualized risk-benefit assessment.\nThese consensus recommendations aim to support informed, context‑appropriate decision‑making and\noptimize long‑term medical management of endometriosis‑associated pain in routine clinical practice.\nCategories:\n Urology, Obstetrics/Gynecology, Pain Management\nKeywords:\n elagolix, endometriosis, endometriosis-related pain, gnrh antagonist, indian consensus\nIntroduction And Background\nIn India, endometriosis poses a significant clinical and socioeconomic burden, affecting an estimated 42\nmillion women \n[1]\n. It contributes to dysmenorrhea (77%), chronic pelvic pain (34%), and dyspareunia (23%)\n[2]\n. Endometriosis is also reported in up to 30% of adolescent girls presenting with secondary dysmenorrhea\n[1]\n. Furthermore, among infertile women undergoing diagnostic laparoscopy in Indian tertiary care centers,\nendometriosis was identified in 22.3%-48.4% of women, highlighting its substantial contribution to\ninfertility in clinical practice \n[3,4]\n. Beyond its physical manifestations, endometriosis is strongly associated\nwith anxiety, depression, reduced productivity, and impaired social functioning, collectively contributing to\nsubstantial socioeconomic burden and a marked decline in quality of life \n[5,6]\n. Pharmacological\nmanagement for endometriosis has evolved from non-steroidal anti-inflammatory drugs (NSAIDs) and\nestrogen-progesterone combined pills to progestins, and later to gonadotropin-releasing hormone (GnRH)\nagonists and antagonists. While NSAIDs and combined oral contraceptives (COCPs) can reduce\ninflammatory symptoms, they have a limited impact on disease progression and often fail to provide\nadequate and sustained control of chronic pain or address infertility \n[7]\n. Progestins such as dienogest have\ndemonstrated efficacy in reducing pelvic pain and preventing post-surgical recurrence in long-term studies\n[8]\n. However, bleeding irregularities and mood-related adverse effects are among the more commonly\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n15\n15\n \nOpen Access Review Article\nHow to cite this article\nGupte S, T R, Nayyar K D, et al. (November 09, 2026) Elagolix for Endometriosis-Associated Pain: A Narrative Review and Indian Expert\nConsensus. Cureus 18(11): e119395. \nDOI 10.7759/cureus.119395\n\nreported adverse events with dienogest. Changes in bone mineral density (BMD) are generally small in adult\nwomen but may be of greater concern in adolescents and younger patients \n[9]\n.\nLater, GnRH agonists became a mainstay for moderate to severe endometriosis pain, acting through\npituitary receptor downregulations \n[10]\n. Nevertheless, their use is limited by an initial symptom flare,\npronounced hypoestrogenic adverse effects (including vasomotor symptoms and bone loss), parenteral\nadministration, and the requirement for add-back therapy to mitigate side effects and preserve bone health\n[10,11]\n.\nGnRH antagonists induce a rapid onset of clinical effects, without the flare-up effect seen with agonists.\nGnRH antagonists have been used for the treatment of pathological conditions, such as endometriosis and\nuterine fibroids. Elagolix, an oral non-peptide GnRH antagonist, was recently approved in India for\nmoderate to severe pain associated with endometriosis and has demonstrated its efficacy and an acceptable\nsafety profile in global clinical trials \n[12]\n.\nIn addition to elagolix, other oral GnRH antagonists have demonstrated efficacy in the management of\nendometriosis-associated pain. Relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, and\nnorethisterone acetate 0.5 mg) significantly improved dysmenorrhea and non-menstrual pelvic pain\ncompared with placebo in the phase 3 SPIRIT 1 and SPIRIT 2 trials, while minimizing bone mineral density\nloss through concomitant add-back therapy \n[13]\n. Similarly, linzagolix demonstrated significant reductions in\nendometriosis-associated pain in the phase 3 EDELWEISS 3 trial, with sustained efficacy observed in the\nEDELWEISS 6 extension study \n[14]\n. These findings support the expanding role of oral GnRH antagonists in\nendometriosis management \n[15]\n. However, while relugolix-containing therapies are approved in India for\nuterine fibroids, they are not currently approved for endometriosis-associated pain, and linzagolix is\ncurrently neither approved nor available in India \n[16]\n.\nRationale of consensus\nElagolix received regulatory approval in India in August 2024 and is supported by global evidence for the\nmanagement of endometriosis‑associated pain \n[13,16]\n. Currently, there are no published studies evaluating\nits use in Indian patients with endometriosis. To address this evidence gap and provide context‑relevant use\nin routine Indian clinical practice, an expert consensus was developed.\nReview\nMethodology\nThe development of consensus statements on the role of elagolix in endometriosis care within the Indian\nclinical context required a structured, transparent, and inclusive approach to address real-world practice.\nWe considered a structured modified Delphi approach to generate clinically actionable consensus\nstatements. In this, we incorporated face-to-face discussion after the development of draft statements by\nthe steering committee. This allowed experts to clarify interpretations, examine evidence collectively, and\nresolve disagreements through discussion. Since the 5-point Likert scale is simple, familiar, and widely used\nin the modified Delphi approach, we incorporated this voting method. This helped us capture expert\nagreement more clearly and in a way that aligns well with current Indian consensus practices \n[17]\n. This\ninitiative is aimed at developing consensus-based recommendations for the diagnosis and management of\nendometriosis in India, with particular emphasis on women who are not currently seeking infertility\ntreatment \n[18]\n.\nSteering committee\nA steering committee comprising six obstetrics and gynecology experts was constituted to lead the\nconsensus process. Members were selected based on their clinical expertise (>15 years of experience) in\ngynecology, academic contributions to the field, and willingness to participate. The steering committee was\nresponsible for drafting the initial consensus statements.\nDevelopment of draft consensus statements\nThe consensus process began with a literature review conducted by a steering committee to identify\nknowledge gaps and formulate preliminary statements. A literature search was performed in PubMed,\nGoogle Scholar, and the Cochrane Library using terms such as “elagolix,” “endometriosis,” “GnRH\nantagonists,” “endometriosis in India,” “endometriosis guidelines,” “consensus,” and “endometriosis pain\nmanagement,” restricted to publications from 2015 to 2025. Based on the evidence retrieved, 13 provisional\nstatements were drafted across three domains: diagnosis, management of endometriosis, and role of\nelagolix.\nConstitution of expert panel\nConsidering the heterogeneity in the patient population and endometriosis care, experts were selected to\n \n2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395\n2\n of \n14\n\nensure broad geographic representation across the country. A total of 74 experts were organized into 6\nexpert panels; a total of 12 obstetrics and gynecology specialists were part of each of the 5 expert panels,\nand in the sixth expert panel, a total of 14 obstetrics and gynecology specialists were involved. Selection of\nexperts was based on predefined inclusion criteria, which required a minimum of 10 years of clinical\nexperience.\nRefinement of consensus statements through regional panel meetings\nA total of six round-table meetings were conducted across India to refine the preliminary consensus\nstatements. Sites included Chennai, Delhi, Hyderabad, Mumbai, Nagpur, and Pune. At each site, a two-hour\nmeeting was conducted, which followed a standardized agenda: (a) presentation of current statements with\nsupporting evidence (20 minutes) and (b) discussion of each statement among the experts based on real\nclinical practice and guideline recommendations. Across these meetings, 42 actionable suggestions were\ngenerated. Based on collective expert deliberation, 2 statements were removed (Appendix I), and the final\nset of 11 consensus statements was established (Figure \n1\n).\nFIGURE\n 1: Modified Delphi approach for the consensus development\nConsensus validation\nIndependent validation of the finalized statements was conducted using a 5‑point Likert scale anonymous\nvoting process involving all 74 experts. The finalized 11 draft statements were circulated to all the experts\nvia mail, and responses were collected through a structured Google Form. The voting options included\n“accept completely,” “accept with some reservations,” “accept with major reservations,” “reject with\nreservations,” and “reject completely.” A statement was labeled “accepted” if ≥75% of respondents selected\neither “accept completely” or “accept with some reservations”. Similarly, a statement was considered\nrejected if 75% or more of the participants opted for “reject completely” or “reject with\nreservations.” Consensus voting was used only to determine agreement with the statements.\nFor statements that achieved consensus, the Level of Evidence (LoE) and Strength of Evidence (SoE) were\nassigned separately by the steering committee based on appraisal of the supporting literature using a\nmodified framework adapted from the Canadian Task Force on the Periodic Health Examination, as\nsummarized in Table \n1\n \n[19]\n.\n \n2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395\n3\n of \n14\n\nQuality of Evidence\nStrength of Evidence\nGrade\nDescription\nGrade\nDescription\nI\nEvidence obtained from at least one RCT\nA\nThere is good evidence to support the\nstatement\nII-1\nEvidence from well-controlled trials without randomization\nB\nThere is fair evidence to support the\nstatement\nII-2\nEvidence from a well-designed cohort or case-control study\nC\nThere is poor evidence to support the\nstatement\nII-3\nEvidence from comparisons between time or place with or without\nintervention\nD\nThere is fair evidence to refute the statement\nIII\nOpinion of experienced authorities and expert committees\nE\nThere is good evidence to refute the\nstatement\nTABLE\n 1: Quality and Strength of Evidence\nRCT: randomized controlled trial\nEthical approval\nEthical approval was not required for this consensus study, as the recommendations were developed through\nexpert opinion and review of published literature, without the involvement of patients, human participants,\nor identifiable personal data.\nExpert consensus\nEvaluation and Diagnosis of Endometriosis\nStatement 1: Awareness, early referral, and timely management of endometriosis can reduce morbidity and\nrecurrence, and improve quality of life (consensus percentage: 100% (accept completely: 83.8%, accept with\nsome reservation: 16.2%), LoE: II-2, SoE: C).\nInternational guidelines consistently emphasize early recognition and referral to reduce diagnostic delay\nand improve outcomes. The 2022 ESHRE and 2024 NICE guidelines strongly recommend prompt evaluation\nand referral to specialized care pathways to minimize disease progression and enhance quality of life \n[20,21]\n.\nEvidence from a systematic review and meta‑analysis shows that postoperative dienogest therapy\nsignificantly reduces recurrence after conservative surgery compared with no postoperative hormonal\ntreatment, underscoring the broader principle that early and appropriate medical management can mitigate\nrecurrence risk \n[22]\n. Additionally, a prospective cohort study of 205 women reported greater quality-of-life\nimprovement when treatment was initiated at earlier stages of disease, reinforcing the clinical value of early\nintervention \n[23]\n. Collectively, these findings highlight that awareness, early referral, and timely\nmanagement are pivotal determinants of long‑term outcomes in endometriosis care.\nStatement 2: A comprehensive evaluation with detailed menstrual, family, and systemic history is essential,\nas non-specific cyclical or persistent symptoms may indicate underlying endometriosis (consensus\npercentage: 100% (accept completely: 63.5%, accept with some reservation: 36.5%), LoE: III, SoE: B).\nDiagnosis of endometriosis remains largely symptom-driven, and a normal ultrasound does not exclude\ndisease when clinical suspicion is high. ESHRE and NICE guidelines emphasize comprehensive history\ntaking, including menstrual characteristics, pain patterns, infertility history, and family history, to reduce\ndiagnostic delay \n[20,21]\n. A large prospective two-phase observational study across 19 hospitals (n=1,396)\ndemonstrated that structured symptom-based models modestly predicted any-stage disease (area under the\ncurve (AUC): ~0.68) and more accurately predicted stage III/IV disease (AUC: ~0.85), supporting systematic\nhistory and symptom phenotyping to prioritize referral pathways \n[24]\n. Familial predisposition further\nstrengthens clinical suspicion. NICE-based summaries and observational data indicate that a first-degree\nrelative with endometriosis increases disease likelihood and may be associated with advanced-stage\npresentation \n[25,26]\n. Implementing standardized history parameters and structured pain phenotyping in\noutpatient settings may help shorten diagnostic pathways and align management with patient goals.\nStatement 3: In women with suspected endometriosis, transvaginal ultrasound (TVUS) is the preferred first-\nline investigation, with transabdominal ultrasound or magnetic resonance imaging (MRI) reserved for\n \n2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395\n4\n of \n14\n\nclinically indicated cases (consensus percentage: 91.9% (accept completely: 70.3%, accept with some\nreservation: 21.6%), LoE: II-1, SoE: A).\nMeta-analyses confirm that transvaginal ultrasound (TVUS) has high diagnostic accuracy for deep\nendometriosis, with a pooled sensitivity of 0.85 and a specificity of 0.92, comparable to magnetic resonance\nimaging (MRI) (sensitivity: 0.83, specificity: 0.95) \n[27,28]\n. Current ESHRE guidelines recommend skilled\nTVUS as first-line imaging for suspected endometriosis, particularly for ovarian endometriomas and deep\nlesions, with MRI reserved for complex mapping or equivocal findings \n[20]\n. Complementary evidence from\nCochrane reviews and international imaging consensus statements confirms that neither TVUS nor MRI can\nreliably exclude superficial peritoneal disease, but these modalities together provide accurate mapping of\nclinically significant lesions to guide management decisions \n[29,30]\n. Collectively, these data support an\nevidence‑based, resource‑sensitive approach in which TVUS is used first, with MRI or transabdominal\nultrasound reserved for cases where clinically indicated.\nStatement 4: Cancer antigen 125 (CA-125) is not recommended for routine diagnosis or exclusion of\nendometriosis but may be used to monitor disease progression in conservatively managed patients\n(consensus percentage: 91.9% (accept completely: 59.5%, accept with some reservation: 32.4%), LoE: I, SoE:\nA).\nCancer antigen 125 (CA-125) demonstrates limited sensitivity (~52%) but relatively high specificity (~93%)\nat thresholds ≥30 U/mL, functioning as a rule-in rather than rule-out test \n[31]\n. A Cochrane diagnostic review\nconcluded that no blood biomarker, including CA-125, is sufficiently accurate to replace diagnostic\nevaluation or be recommended for routine clinical diagnosis \n[32]\n. However, limited observational data\nsuggest that rising CA-125 levels may correlate with recurrence in select postoperative populations. While\nnot suitable for screening or exclusion, CA-125 may have adjunctive value in longitudinal monitoring under\nspecific clinical circumstances \n[20,21]\n. Overall, CA-125 should not be used to exclude disease but may be\nselectively employed for monitoring in individualized management strategies.\nManagement of Endometriosis\nStatement 5: In women with clinically suspected endometriosis not seeking fertility, empirical therapy with\nprogestins may be initiated prior to or alongside diagnostic modalities (consensus percentage: 90.6% (accept\ncompletely: 56.8%, accept with some reservation: 33.8%), LoE: I, SoE: A).\nMajor guidelines, including ESHRE, NICE, and FOGSI guidelines, endorse empirical hormonal therapy\nwithout mandatory diagnostic laparoscopy in symptomatic women not seeking pregnancy \n[20,21,33]\n. In\nresource-sensitive settings, accessible and cost-effective options such as progestins and levonorgestrel-\nreleasing intrauterine (LNG-IUS) remain pragmatic first-line choices. Empirical therapy should be aligned\nwith patient preferences, bleeding patterns, and tolerability, with symptomatic response guiding further\nescalation \n[20,21,33]\n. Before initiating empirical therapy, appropriate clinical evaluation should be\nundertaken to exclude alternative causes of pelvic pain and clinically significant adnexal pathology that may\nrequire further investigation or management \n[27]\n.\nA meta-analysis of randomized controlled trials (RCTs) demonstrated significant pain reduction compared\nwith placebo (standardized mean difference (SMD): -0.61; 95% confidence interval (CI): -0.77 to -0.45)\n[21,34-36]\n. Contemporary network meta-analyses further confirm the efficacy of progestin-only regimens\nacross pain domains, supporting their role as appropriate initial therapy in symptomatic patients not\npursuing pregnancy \n[34,37]\n.\nStatement 6: In women not seeking fertility, medical therapy, including hormonal interventions, should be\noffered as first-line treatment to reduce endometriosis-associated pelvic pain (consensus percentage: 95.9%\n(accept completely: 60.8%, accept with reservation: 35.1%), LoE: I, SoE: A).\nA 2024 network meta-analysis of 45 RCTs demonstrated consistent reductions in dysmenorrhea,\ndyspareunia, and overall pelvic pain with combined oral contraceptives (COCPs) and progestins compared\nwith placebo \n[38]\n. Long-term randomized data (PRE-EMPT trial, n=405) showed sustained pain\nimprovement at three years with either long-acting progestogens or COCPs following surgery, supporting\nthe durability of hormonal suppression strategies \n[39]\n. Guidelines consistently recommend NSAIDs\ncombined with hormonal suppression as first-line therapy, reserving surgery for refractory symptoms,\ncomplications, or fertility indications \n[20,40]\n. These findings reinforce medical therapy as the cornerstone of\ninitial management in non-fertility-seeking women, with shared decision-making central to optimizing\nlong-term adherence and outcomes.\nElagolix in the Management of Endometriosis Pain\nElagolix is an oral, non-peptide GnRH receptor antagonist. Elagolix 150 mg and 200 mg tablets were\napproved for the management of moderate to severe pain associated with endometriosis by the US FDA in\nJuly 2018 and by the Drugs Controller General of India (DCGI) in August 2024. In women with normal liver\n \n2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395\n5\n of \n14\n\nfunction or mild hepatic impairment (Child-Pugh A), elagolix is typically prescribed at 150 mg once daily for\nup to 24 months; however, in those experiencing significant dyspareunia, a higher dose of 200 mg twice\ndaily may be used for a shorter duration of up to 6 months. For patients with moderate hepatic impairment\n(Child-Pugh B), treatment should be limited to 150 mg once daily for no more than six months. Elagolix is\ncontraindicated during pregnancy, in women with osteoporosis or severe hepatic dysfunction (Child-Pugh\nC), and in those receiving strong Organic Anion Transporting Polypeptide 1B1 (OATP1B1) inhibitors \n[41]\n.\nPharmacokinetic evaluations demonstrate rapid oral absorption (median time to peak concentration ≈ 1\nhour). Plasma protein binding was 80%. Exposure (area under the plasma concentration-time curve (AUC))\nand Cmax were reduced by 24 and 36%, respectively, when elagolix was administered with a high-fat meal\nrelative to fasting. The elimination half-life is approximately 4-6 hours. The pharmacokinetic properties of\nelagolix are not affected to a clinically meaningful extent by body weight, body mass index, or race/ethnicity\n[42]\n.\nElagolix binds competitively to pituitary GnRH receptors, blocking endogenous GnRH signaling. Elagolix\nproduces rapid and dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating\nhormone (FSH), resulting in reduced ovarian estradiol concentrations and attenuation of estrogen-\ndependent endometriotic activity. In contrast to GnRH agonists, elagolix does not cause an initial flare and\nallows graded suppression of estradiol, with median estradiol levels reduced to approximately 42 pg/mL\nwith 150 mg once daily and 12 pg/mL with 200 mg twice daily in phase 3 studies \n[43,44]\n.\nIn the pivotal ELARIS EM-I and EM-II trials, both 150 mg once daily and 200 mg twice daily regimens\nsignificantly improved dysmenorrhea and non-menstrual pelvic pain compared with placebo at three\nmonths, with sustained responses through six months. Dysmenorrhea responder rates ranged from 43.4% to\n46.4% with elagolix 150 mg once daily and 72.4% to 75.8% with elagolix 200 mg twice daily, compared with\n19.6% to 22.7% with placebo. Corresponding responder rates for non-menstrual pelvic pain were 49.8%-\n50.4% and 54.5%-57.8% with the respective elagolix regimens, compared with 36.5% in placebo-treated\nwomen \n[43]\n. Extension studies further demonstrated maintenance of response up to 12 months in a\nsubstantial proportion of women, alongside improvements in dyspareunia and reductions in rescue\nanalgesic use, translating into clinically meaningful enhancement of patient-reported outcomes and quality\nof life \n[45]\n. Across trials, elagolix was generally well tolerated; the most common adverse events included hot\nflushes, headache, nausea, insomnia, and mood changes, with dose-dependent decreases in bone mineral\ndensity (BMD) supporting defined duration limits of therapy.\nDose-dependent increases in serum lipid parameters, including low-density lipoprotein (LDL) cholesterol\nand triglycerides, have also been observed with elagolix therapy \n[46,47]\n.\nMost clinical guidelines recommend GnRH antagonists such as elagolix as a second‑line treatment for\nendometriosis. A substantial number of women with endometriosis exhibit progesterone resistance, which\ncan limit the effectiveness of progestin‑based therapies. Elagolix provides a mechanistically appropriate\noption for these patients, offering therapeutic benefit when progestins fail to produce adequate results.\nCollectively, its oral administration, rapid onset, dose flexibility, and well-characterized benefit-risk profile\nposition elagolix as a valuable therapeutic option within individualized, long-term management strategies\nfor endometriosis-associated pain \n[42]\n.\nStatement 7: There is clinical evidence supporting elagolix for the management of endometriosis-associated\npelvic pain, although it is not necessarily the first-line therapy (consensus percentage: 89.2% (accept\ncompletely: 67.6%, accept with reservation: 21.6%), LoE: I, SoE: A).\nPhase 3 trials of elagolix demonstrated significant reductions in dysmenorrhea and non-menstrual pelvic\npain with elagolix compared to placebo at three months and sustained till six months \n[43]\n. A systematic\nreview/meta‑analysis validates these benefits across pain domains (overall pain, dysmenorrhea,\nnon‑menstrual pelvic pain, and dyspareunia), while noting higher rates of non‑serious adverse events\nrelative to placebo \n[44]\n. Long-term extension studies demonstrate sustained pain reduction for up to 12\nmonths; however, dose‑related decreases in BMD may occur and require monitoring of bone health \n[45]\n.\nThese findings establish elagolix as an effective therapeutic option, typically positioned after failure or\nintolerance of first-line hormonal therapies.\nStatement 8: Elagolix 150 mg once daily is recommended for moderate to severe pain associated with\nendometriosis for up to 24 months. Elagolix 200 mg BID is a considerable option for moderate to severe pain\nassociated with dyspareunia for 6 months, followed by 150 mg once daily (consensus percentage: 93.3%\n(accept completely: 67.6%, accept with reservation: 25.7%), LoE: I, SoE: A).\nDosing of elagolix should be individualized according to symptom severity and patient characteristics. The\n150 mg once-daily regimen may be administered for up to 24 months in women with moderate symptoms,\nwhereas the 200 mg twice-daily regimen is recommended for up to 6 months in those with severe pain,\nparticularly when dyspareunia is prominent. Limitation of treatment duration is dose-dependent and driven\nby a reduction in BMD due to reduced estrogen level; elagolix is contraindicated in severe hepatic\n \n2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395\n6\n of \n14\n\nimpairment and requires restriction in moderate hepatic impairment \n[43,46]\n.\nEfficacy and dose selection are supported by phase 3 trials and meta-analyses. In the ELARIS EM-I and EM-II\nstudies (N≈1,700), both 150 mg once daily and 200 mg twice daily significantly improved dysmenorrhea and\nnon-menstrual pelvic pain compared with placebo at 3-6 months, demonstrating clear dose-dependent\neffects. Improvements in dyspareunia were more pronounced and consistent with the 200 mg twice-daily\nregimen, supporting its use in women with prominent dyspareunia. Long-term extension studies (EM-III\nand EM-IV) confirmed maintenance of pain relief for up to 12 months, while also demonstrating dose-\nrelated declines in BMD that justify defined duration limits and step-down strategies \n[43,45,46]\n.\nStatement 9: Elagolix can be considered as an alternative option for women with endometriosis-associated\npelvic pain not responding to prior therapies (consensus percentage: 89.2% (accept completely: 62.2%,\naccept with reservation: 27.0%), LoE: II-3, SoE: B).\nFor women with inadequate response or intolerance to prior therapies (e.g., progestins/COCPs), elagolix is a\nreasonable alternative, supported by extension studies (EM-III and EM-IV) demonstrating sustained efficacy\nand acceptable safety over 12 months. Advantages include rapid onset, no flare, oral administration,\npredictable reversibility, and the option of add‑back therapy to support longer‑term tolerability \n[45,48]\n. In\nIndia, elagolix provides a non‑injectable choice aligned with patient preferences; selection should consider\ncost, access, and monitoring capacity \n[49,50]\n.\nStatement 10: Compared to GnRH agonists, elagolix 150 mg once daily for up to 24 months reported lower\nbone mineral density-related side effects, minimizing the need for add-back therapy (consensus percentage:\n91.9% (accept completely: 55.4%, accept with reservation: 36.5%), LoE: III, SoE: C).\nElagolix shows dose-dependent BMD reduction, smaller at 150 mg QD than at 200 mg BID, and does not\nmandate add-back therapy as per label \n[46,48]\n.\nA recent systematic review and meta-analysis of randomized controlled trials reported significantly less\nbone mineral density reduction with GnRH antagonists than with GnRH agonists. However, bone mineral\ndensity changes remain dose- and duration-dependent and should be considered when selecting treatment\nduration and monitoring strategies \n[51]\n.\nEmerging evidence suggests that concomitant add-back therapy (estradiol 1 mg plus norethindrone acetate\n0.5 mg) may attenuate BMD loss during extended treatment, particularly when higher doses are used \n[52]\n.\nAccordingly, clinicians should proactively counsel patients that elagolix may cause dose‑related\nhypoestrogenic adverse effects, most commonly hot flushes/night sweats, headache, nausea, insomnia, and\nmood changes, which are generally more frequent at higher doses. Given the dose‑ and duration‑dependent\nimpact on bone mineral density, therapy should be aligned to the lowest effective dose and appropriate\nduration, with bone health risk assessment (and BMD assessment when clinically indicated) incorporated\ninto follow‑up, particularly in women with additional risk factors \n[46,47,53]\n.\nPatients should be informed that menstrual bleeding may decrease or stop, which can reduce the ability to\nrecognize pregnancy, and pregnancy testing should be performed if pregnancy is suspected. We recommend\nadvising effective non‑hormonal contraception during treatment and for 28 days after discontinuation and\nnoting that estrogen‑containing contraceptives may reduce elagolix efficacy. Clinicians should also counsel\non red flag symptoms and promptly evaluate patients with new or worsening depression/anxiety or suicidal\nideation, or symptoms suggestive of liver injury (e.g., jaundice or dark urine), with reassessment of benefit\nand risk if such events occur \n[46,47,53]\n.\nStatement 11: Elagolix may be considered as a first-line therapy for selected patients with endometriosis,\nsuch as those with dyspareunia (consensus percentage: 90.6% (accept completely: 56.8%, accept with\nreservation: 33.8%), LoE: I, SoE: B).\nAlthough guidelines recommend progestins/COCPs as first-line therapy, the expert panel acknowledged\nscenarios in which elagolix may be an appropriate initial option. These include intolerance or\ncontraindication to estrogen- or progestin-based therapies, patient preference for a non-contraceptive oral\nagent, or the need for rapid, reversible ovarian suppression \n[20]\n.\nProgestin intolerance is clinically relevant in routine practice. Cohort data with dienogest report\ndiscontinuation rates approaching 20% within the first year, most commonly due to irregular bleeding, mood\nchanges, reduced libido, and vaginal dryness \n[54,55]\n.\nIn such women, an oral GnRH antagonist offers a non‑progestin mechanism of action. However, as current\nguidelines do not formally position elagolix as first-line therapy, its use in this context should be\nindividualized and supported by shared decision-making, with appropriate documentation of risks and\n \n2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395\n7\n of \n14\n\nbenefits (Figure \n2\n and Figure \n3\n) \n[31,46]\n.\nFIGURE\n 2: Algorithm for the management of endometriosis\nART: assisted reproductive technology, CA-125: cancer antigen 125, MRI: magnetic resonance imaging, NSAID:\nnon-steroidal anti-inflammatory drug, OC: oral contraceptive, TVUS: transvaginal ultrasound, TAUS:\ntransabdominal ultrasound\nFIGURE\n 3: Elagolix use in endometriosis management\nBMD: bone mineral density, LFT: liver function test\n \n2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395\n8\n of \n14\n\nTo support shared decision‑making and safe, appropriate use of elagolix, patients should be counselled on\nexpected hypoestrogenic effects, contraception requirements, and red flag symptoms. A brief checklist of\nroutine practice is provided in Table \n2\n.\nBefore initiating\nExclude pregnancy (or start within 7 days of menses)\nCounsel: bleeding may reduce/stop, so pregnancy may be harder to recognize\nNon-hormonal contraception during treatment and for 28 days after stopping\nConsider/check baseline lipid profile\nBone risk screen; BMD scan (DEXA) if risk factors for osteoporosis or when treatment beyond 12 months is anticipated; do not use in\nknown osteoporosis\nMood history screen (depression/anxiety/suicidality)\nReview liver history; counsel on liver injury symptoms\nDiscuss treatment cost/affordability\nDuring treatment\nExplain common AEs: hot flush/night sweats, headache, nausea, insomnia, mood changes\nBone protection: calcium/vitamin D + weight-bearing activity\nIf continuing in risk patients, repeat BMD at ~1 year (as clinically indicated)\nFollow-up and stop/urgent review\nSchedule follow-up at 4-6 weeks and ~3 months\nStop if pregnant; evaluate promptly if pregnancy suspected\nUrgent review: new/worsening depression, anxiety, suicidal thoughts/behavior\nUrgent review: jaundice/dark urine or other liver injury symptoms\nTABLE\n 2: Checklist for patient counseling for elagolix\nBMD: bone mineral density, AE: adverse events\nFinal Consensus Statements\nBased on evidence, experts agreed on the following statements in the meeting (Table \n3\n).\n \n2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395\n9\n of \n14\n\nConsensus statements\nConsensus\npercentage\nLoE\nand\nSoE\nSection 1: Evaluation and diagnosis of endometriosis\n1\nAwareness, early referral, and timely management of endometriosis can reduce morbidity and recurrence, and\nimprove quality of life.\n100%\nII-2,\nC\n2\nA comprehensive evaluation with detailed menstrual, family, and systemic history is essential, as non-specific\ncyclical or persistent symptoms may indicate underlying endometriosis.\n100%\nIII,\nB\n3\nIn women with suspected endometriosis, transvaginal ultrasound is the preferred first-line investigation, with\ntransabdominal ultrasound or MRI reserved for clinically indicated cases.\n91.9%\nII-1,\nA\n4\nCA-125 is not recommended for routine diagnosis or exclusion of endometriosis but may be used to monitor\ndisease progression in conservatively managed patients\n91.9%\nI, A\nSection 2: Management of endometriosis and role of elagolix\n5\nIn women with clinically suspected endometriosis not seeking fertility, empirical therapy with progestins may be\ninitiated prior to or alongside diagnostic modalities.\n90.6%\nI, A\n6\nIn women not seeking fertility, medical therapy, including hormonal interventions, should be offered as first-line\ntreatment to reduce endometriosis-associated pelvic pain.\n95.9%\nI, A\n7\nThere is clinical evidence supporting elagolix for the management of endometriosis-associated pelvic pain,\nalthough it is not necessarily the first-line therapy.\n89.2%\nI, A\n8\nElagolix 150 mg OD is recommended for moderate to severe pain associated with endometriosis for up to 24\nmonths. Elagolix 200 mg BID is a considerable option for moderate to severe pain associated with dyspareunia\nfor 6 months, followed by 150 mg OD.\n93.3%\nI, A\n9\nElagolix can be considered as an alternative option for women with endometriosis-associated pelvic pain not\nresponding to prior therapies.\n89.2%\nII-3,\nB\n10\nCompared to GnRH agonists, elagolix 150 mg once daily for up to 24 months reported lower bone mineral\ndensity-related side effects, minimizing the need for add-back therapy.\n91.9%\nIII,\nC\n11\nElagolix may be considered as a first-line therapy for selected patients with endometriosis, such as those with\ndyspareunia.\n90.6%\nI, B\nTABLE\n 3: Final consensus statements\nAll recommendations regarding elagolix in this consensus apply to adult women (≥18 years of age) unless otherwise specified.\nCA-125: cancer antigen 125, LoE: Level of Evidence, MRI: magnetic resonance imaging, OD: once daily, SoE: Strength of Evidence\nLimitations\nThis expert consensus has certain limitations. First, the recommendations are based on a structured\nliterature review and expert opinion rather than a formal systematic review or meta-analysis, which may\nintroduce selection bias. Although the level and strength of evidence were graded using a modified\nframework adapted from the Canadian Task Force on the Periodic Health Examination, the grading process\nrelied on expert assessment and was not supported by a formal systematic evidence review, which may\nintroduce subjectivity in evidence interpretation and recommendation development.\nSecond, the consensus process involved a single round of anonymous voting following regional expert\ndiscussions. While this approach facilitated broad participation, it may have limited opportunities for\niterative refinement of statements and reassessment of areas of disagreement. The expert panel consisted\nexclusively of obstetricians and gynecologists with experience in endometriosis management and therefore\nmay not fully reflect the perspectives of other relevant stakeholders, including reproductive\nendocrinologists, pain specialists, primary care physicians, and multidisciplinary care teams.\nThird, patient representatives were not involved in the consensus development process. Consequently,\npatient preferences, experiences, and patient-reported outcomes may not be fully represented in the final\nrecommendations.\n \n2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395\n10\n of \n14\n\nFourth, although a structured consensus methodology and anonymous expert voting were employed to\nminimize bias, the possibility of perceived conflict of interest cannot be completely excluded.\nFifth, variability in real-world clinical practices and limited India-specific data on elagolix may affect the\ngeneralizability of the recommendations. Furthermore, the scope of this consensus was focused specifically\non elagolix and did not include a systematic comparative evaluation of other GnRH antagonists or\nalternative medical therapies for endometriosis, which may limit broader treatment comparisons.\nFinally, as emerging evidence continues to evolve, some recommendations may require future updates to\nremain aligned with the latest clinical data and guidelines.\nConclusions\nEndometriosis continues to impose a substantial clinical and socioeconomic burden in India, with persistent\ndelays in diagnosis and variability in therapeutic pathways. In the absence of Indian patient-specific data on\nelagolix, this consensus was developed to provide structured, context-relevant guidance for its rational\nintegration into routine practice, particularly among women not seeking fertility. The consensus\nemphasized the “diagnose early, treat early” paradigm, prioritizing skilled transvaginal ultrasonography for\ntimely detection and initiating empirical hormonal therapy in appropriate non-fertility-seeking women to\nreduce morbidity, limit recurrence, and improve quality of life. Within this framework, elagolix represents\nan oral GnRH antagonist that offers rapid, titratable suppression without flare, aligning well with patient\npreferences for non‑injectable, reversible therapy in routine practice. Across phase 3 trials and extension\nstudies, elagolix has demonstrated clinically meaningful reductions in dysmenorrhea and non‑menstrual\npelvic pain, with the 200\nmg BID regimen showing utility when dyspareunia is a prominent symptom; the\n150\nmg OD regimen provides durable control for up to 24\nmonths in appropriately selected patients. When\nindividualized through shared decision‑making, considering bone health, mood, hepatic status, and\ncontraceptive counseling, elagolix can help more patients realize the benefits of medical management\nearlier in their disease course.\nThis consensus provides practical direction for patient selection, dosing, monitoring, and positioning of\nelagolix in endometriosis care. Future research should generate real-world Indian data, clarify optimal\nsequencing and add-back strategies, and explore the role of GnRH antagonism in related gynecologic\nconditions such as adenomyosis and uterine fibroids, thereby strengthening the long-term evidence base for\npersonalized endometriosis management.\nAppendices\nAppendix I\nThe two statements that were excluded from the final consensus are shown in Table \n4\n.\nStatement\nConsensus outcome\nElagolix may be considered for heavy menstrual bleeding associated with uterine\nleiomyomas in premenopausal women.\nExcluded from final consensus due to off-\nlabel indication\nGnRH antagonists (elagolix) may be considered for uterine fibroids with coexisting\nadenomyosis.\nExcluded from final consensus due to off-\nlabel indication\nTABLE\n 4: Statements excluded from the final consensus\nAdditional Information\nAuthor Contributions\nAll authors have reviewed the final version to be published and agreed to be accountable for all aspects of the\nwork.\nAcquisition, analysis, or interpretation of data:\n  \nKamal Kumar, Rooma Sinha, Jeyarani Kamaraj, Jayanthi\nReddy, Mala Raj, Parag Biniwale, Sushma Deshmukh, Chaitanya Ganpule, Sachin Kulkarni, Neeraj Kumar, K\nD. Nayyar\nDrafting of the manuscript:\n  \nKamal Kumar, Neeraj Kumar\nSupervision:\n  \nKamal Kumar, Onkar C. Swami\n \n2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395\n11\n of \n14\n\nConcept and design:\n  \nSanjay Gupte, Ramanidevi T, PM Gopinath, Girija Wagh, Onkar C. Swami, Shivani S.\nGour\nCritical review of the manuscript for important intellectual content:\n  \nSanjay Gupte, Ramanidevi T, PM\nGopinath, Rooma Sinha, Jeyarani Kamaraj, Jayanthi Reddy, Mala Raj, Girija Wagh, Parag Biniwale, Sushma\nDeshmukh, Chaitanya Ganpule, Sachin Kulkarni, Onkar C. Swami, K D. Nayyar, Shivani S. Gour\nDisclosures\nConflicts of interest:\n In compliance with the ICMJE uniform disclosure form, all authors declare the\nfollowing: \nPayment/services info:\n All authors have declared that no financial support was received from\nany organization for the submitted work. \nFinancial relationships:\n All declare(s) Funding for publication\nfrom Alembic Pharmaceuticals Ltd. Alembic Pharmaceuticals Ltd. supported the article processing and\npublication charges for this manuscript. Dr. Onkar Swami, Dr. Kamal Kumar, and Mr. Neeraj Kumar\ndeclare(s) employment from Alembic Pharmaceuticals Ltd., which actively markets Elagolix. \nOther\nrelationships:\n All authors have declared that there are no other relationships or activities that could appear\nto have influenced the submitted work.\nAcknowledgements\nThe authors extend sincere thanks to the 74 clinicians who actively participated in the discussions during\nthe expert meeting and were instrumental in the development of the consensus statements presented in this\nmanuscript. The authors would also like to thank Dr. Heena Bhojwani and Ms. Divya Aher for reviewing,\nediting, and submitting this manuscript. The artificial intelligence (AI) tool Microsoft Copilot was utilized to\nassist with language refinement and grammar correction.\nReferences\n1\n. \nGajbhiye RK: \nEndometriosis and inflammatory immune responses: Indian experience\n. Am J Reprod\nImmunol. 2023, 89:e13590. \n10.1111/aji.13590\n2\n. \nBendigeri T, Warty N, Sawant R, et al.: \nEndometriosis: clinical experience of 500 patients from India\n. Indian\nPract. 2015, 68:33-40.\n3\n. \nVarghese N, Shanmugam I, Sivamani H, Durairaj A: \nPrevalence and risk factors of endometriosis among\ninfertile women in a tertiary care center in South India\n. Cureus. 2024, 16:e71772. \n10.7759/cureus.71772\n4\n. \nMishra VV, Gaddagi RA, Aggarwal R, Choudhary S, Sharma U, Patel U: \nPrevalence; characteristics and\nmanagement of endometriosis amongst infertile women: a one year retrospective study\n. J Clin Diagn Res.\n2015, 9:QC01-3. \n10.7860/JCDR/2015/13687.6125\n5\n. \nPerricos A, Wenzl R: \nRecent advances in endometriosis pathophysiology and pharmacological treatment\n. Int\nJ Mol Sci. 2024, 25:\n10.3390/ijms25126575\n6\n. \nElizur SE, Mostafa J, Berkowitz E, Orvieto R: \nEndometriosis and infertility: pathophysiology, treatment\nstrategies, and reproductive outcomes\n. Arch Gynecol Obstet. 2025, 312:1037-48. \n10.1007/s00404-025-\n08124-1\n7\n. \nRafique S, Decherney AH: \nMedical management of endometriosis\n. Clin Obstet Gynecol. 2017, 60:485-96.\n10.1097/GRF.0000000000000292\n8\n. \nCapezzuoli T, Vannuccini S, Mautone D, et al.: \nLong-term hormonal treatment reduces repetitive surgery for\nendometriosis recurrence\n. Reprod Biomed Online. 2021, 42:451-6. \n10.1016/j.rbmo.2020.09.018\n9\n. \nMurji A, Biberoğlu K, Leng J, Mueller MD, Römer T, Vignali M, Yarmolinskaya M: \nUse of dienogest in\nendometriosis: a narrative literature review and expert commentary\n. Curr Med Res Opin. 2020, 36:895-907.\n10.1080/03007995.2020.1744120\n10\n. \nSurrey ES: \nGnRH agonists in the treatment of symptomatic endometriosis: a review\n. F S Rep. 2023, 4:40-5.\n10.1016/j.xfre.2022.11.009\n11\n. \nDonnez J, Dolmans MM: \nGnRH antagonists with or without add-back therapy: a new alternative in the\nmanagement of endometriosis?\n. Int J Mol Sci. 2021, 22:\n10.3390/ijms222111342\n12\n. \nMartínez-Núñez EN, Carvallo-Ruiz DE, Núñez-Troconis JT: \nGynecological uses of GnRH antagonists: review\narticle\n. Obstet Gynecol Int J. 2022, 13:226-38. \n10.15406/ogij.2022.13.00654\n13\n. \nGiudice LC, As-Sanie S, Arjona Ferreira JC, et al.: \nOnce daily oral relugolix combination therapy versus\nplacebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind,\nstudies (SPIRIT 1 and 2)\n. Lancet. 2022, 399:2267-79. \n10.1016/S0140-6736(22)00622-5\n14\n. \nDonnez J, Becker C, Taylor H, et al.: \nLinzagolix therapy versus a placebo in patients with endometriosis-\nassociated pain: a prospective, randomized, double-blind, phase 3 study (EDELWEISS 3)\n. Hum Reprod. 2024,\n39:1208-21. \n10.1093/humrep/deae076\n15\n. \nDonnez J, Taylor HS, Taylor RN, et al.: \nTreatment of endometriosis-associated pain with linzagolix, an oral\ngonadotropin-releasing hormone-antagonist: a randomized clinical trial\n. Fertil Steril. 2020, 114:44-55.\n10.1016/j.fertnstert.2020.02.114\n16\n. \nCentral Drugs Standard Control Organisation: CDSCO approved drugs/vaccines/r-DNA/blood product\n.\n(2026). Accessed: August 7, 2026: \nhttps://cdscoonline.gov.in/CDSCO/cdscoDrugs\n.\n17\n. \nNasa P, Jain R, Juneja D: \nDelphi methodology in healthcare research: how to decide its appropriateness\n.\nWorld J Methodol. 2021, 11:116-29. \n10.5662/wjm.v11.i4.116\n18\n. \nMurphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, Marteau T: \nConsensus\ndevelopment methods, and their use in clinical guideline development\n. Health Technol Assess. 1998, 2:1-88.\n10.3310/hta2030\n19\n. \nThe Periodic Health Examination: 2. 1984 update. Canadian Task Force on the Periodic Health Examination\n.\n \n2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395\n12\n of \n14\n\nCan Med Assoc J. 1984, 130:1278-85.\n20\n. \nBecker CM, Bokor A, Heikinheimo O, et al.: \nESHRE guideline: endometriosis\n. Hum Reprod Open. 2022,\n2022:hoac009. \n10.1093/hropen/hoac009\n21\n. \nEndometriosis: Diagnosis and Management\n. National Institute for Health and Care Excellence (NICE),\nLondon; 2024.\n22\n. \nZakhari A, Edwards D, Ryu M, Matelski JJ, Bougie O, Murji A: \nDienogest and the risk of endometriosis\nrecurrence following surgery: a systematic review and meta-analysis\n. J Minim Invasive Gynecol. 2020,\n27:1503-10. \n10.1016/j.jmig.2020.05.007\n23\n. \nKaveh M, Moghadam MN, Safari M, Chaichian S, Kashi AM, Afshari M, Sadegi K: \nThe impact of early\ndiagnosis of endometriosis on quality of life\n. Arch Gynecol Obstet. 2025, 311:1415-21. \n10.1007/s00404-025-\n07999-4\n24\n. \nNnoaham KE, Hummelshoj L, Kennedy SH, Jenkinson C, Zondervan KT: \nDeveloping symptom-based\npredictive models of endometriosis as a clinical screening tool: results from a multicenter study\n. Fertil Steril.\n2012, 98:692-701.e5. \n10.1016/j.fertnstert.2012.04.022\n25\n. \nMetzler JM, Imesch P, Dietrich H, Knobel C, Portmann L, Neumeier MS, Merki-Feld GS: \nImpact of family\nhistory for endometriosis, migraine, depression and early menopause on endometriosis symptoms,\nlocalization and stage: a case control study\n. Eur J Obstet Gynecol Reprod Biol. 2024, 293:36-43.\n10.1016/j.ejogrb.2023.12.016\n26\n. \nRajesh S, Mehmeti A, Smith-Walker T, Kendall B: \nDiagnosis and management of endometriosis: summary\nof updated NICE guidance\n. BMJ. 2025, 388:q2782. \n10.1136/bmj.q2782\n27\n. \nDaniilidis A, Grigoriadis G, Dalakoura D, D'Alterio MN, Angioni S, Roman H: \nTransvaginal ultrasound in the\ndiagnosis and assessment of endometriosis-an overview: how, why, and when\n. Diagnostics (Basel). 2022,\n12:\n10.3390/diagnostics12122912\n28\n. \nXu Z, Li Y, Wang Y, Wan Y, Chen J: \nTransvaginal ultrasound and magnetic resonance imaging in detecting\nrectosigmoid deep infiltrating endometriosis: a comparative meta-analysis\n. Front Med (Lausanne). 2025,\n12:1552185. \n10.3389/fmed.2025.1552185\n29\n. \nNisenblat V, Bossuyt PM, Farquhar C, Johnson N, Hull ML: \nImaging modalities for the non-invasive\ndiagnosis of endometriosis\n. Cochrane Database Syst Rev. 2016, 2:CD009591.\n10.1002/14651858.CD009591.pub2\n30\n. \nCondous G, Gerges B, Thomassin-Naggara I, et al.: \nNon-invasive imaging techniques for diagnosis of pelvic\ndeep endometriosis and endometriosis classification systems: an international consensus statement()\n. Hum\nReprod Open. 2024, 2024:hoae029. \n10.1093/hropen/hoae029\n31\n. \nHirsch M, Duffy J, Davis CJ, Nieves Plana M, Khan KS: \nDiagnostic accuracy of cancer antigen 125\nfor endometriosis: a systematic review and meta-analysis\n. BJOG. 2016, 123:1761-8. \n10.1111/1471-\n0528.14055\n32\n. \nNisenblat V, Bossuyt PM, Shaikh R, et al.: \nBlood biomarkers for the non-invasive diagnosis of endometriosis\n.\nCochrane Database Syst Rev. 2016, 2016:CD012179. \n10.1002/14651858.CD012179\n33\n. \nBarbara G, Buggio L, Facchin F, Vercellini P: \nMedical treatment for endometriosis: tolerability, quality of\nlife and adherence\n. Front Glob Womens Health. 2021, 2:729601. \n10.3389/fgwh.2021.729601\n34\n. \nMitchell JB, Chetty S, Kathrada F: \nProgestins in the symptomatic management of endometriosis: a meta-\nanalysis on their effectiveness and safety\n. BMC Womens Health. 2022, 22:526. \n10.1186/s12905-022-02122-0\n35\n. \nFOGSI-ICOG Good Clinical Practice Recommendations (GCPR) Updates in Endometriosis Management\n.\nEndometriosis Committee, 2026.\n36\n. \nVercellini P, Buggio L, Berlanda N, Barbara G, Somigliana E, Bosari S: \nEstrogen-progestins and progestins for\nthe management of endometriosis\n. Fertil Steril. 2016, 106:1552-71.e2. \n10.1016/j.fertnstert.2016.10.022\n37\n. \nAs-Sanie S, Mackenzie SC, Morrison L, Schrepf A, Zondervan KT, Horne AW, Missmer SA: \nEndometriosis: a\nreview\n. JAMA. 2025, 334:64-78. \n10.1001/jama.2025.2975\n38\n. \nCsirzó Á, Kovács DP, Szabó A, et al.: \nComparative analysis of medical interventions to alleviate\nendometriosis-related pain: a systematic review and network meta-analysis\n. J Clin Med. 2024,\n13:\n10.3390/jcm13226932\n39\n. \nCooper KG, Bhattacharya S, Daniels JP, et al.: \nLong acting progestogens versus combined oral contraceptive\npill for preventing recurrence of endometriosis related pain: the PRE-EMPT pragmatic, parallel group, open\nlabel, randomised controlled trial\n. BMJ. 2024, 385:e079006. \n10.1136/bmj-2023-079006\n40\n. \nPatel M: \nRecent trends in medical management of endometriosis\n. J Obstet Gynaecol India. 2024, 74:479-83.\n10.1007/s13224-024-02097-y\n41\n. \nLamb YN: \nElagolix: first global approval\n. Drugs. 2018, 78:1501-8. \n10.1007/s40265-018-0977-4\n42\n. \nShebley M, Polepally AR, Nader A, et al.: \nClinical pharmacology of elagolix: an oral gonadotropin-releasing\nhormone receptor antagonist for endometriosis\n. Clin Pharmacokinet. 2020, 59:297-309. \n10.1007/s40262-\n019-00840-7\n43\n. \nTaylor HS, Giudice LC, Lessey BA, et al.: \nTreatment of endometriosis-associated pain with elagolix, an oral\nGnRH antagonist\n. N Engl J Med. 2017, 377:28-40. \n10.1056/NEJMoa1700089\n44\n. \nQuishpe M, Endara-Mina J, Caizapanta J, et al.: \nEfficacy of elagolix and relugolix for the treatment of pelvic\npain in patients with endometriosis: a systematic review\n. Cureus. 2025, 17:e92149. \n10.7759/cureus.92149\n45\n. \nSurrey E, Taylor HS, Giudice L, et al.: \nLong-term outcomes of elagolix in women with endometriosis: results\nfrom two extension studies\n. Obstet Gynecol. 2018, 132:147-60. \n10.1097/AOG.0000000000002675\n46\n. \nElagolix prescribing information\n. (2026). Accessed: August 7, 2026:\nhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210450s004s005s006lbl.pdf\n.\n47\n. \nLeyland N, Estes SJ, Lessey BA, Advincula AP, Taylor HS: \nA clinician’s guide to the treatment of\nendometriosis with elagolix\n. J Womens Health (Larchmt). 2021, 30:569-78. \n10.1089/jwh.2019.8096\n48\n. \nArcher DF, Watts N, Gallagher C, et al.: \nLong-term effect of elagolix on bone mineral density: results from\ntwo phase 3 extension studies in women with endometriosis-associated pain\n. Fertil Steril. 2017, 108:E95.\n10.1016/j.fertnstert.2017.07.292\n49\n. \nBetiuk Z, Błażyca M, Bartoszczyk M, Kutyła K, Gierulska N, Tarkowski R, Kułak K: \nCurrent evidence and\nemerging directions in endometriosis pharmacotherapy: a systematic review of recent advances\n. J Clin Med.\n \n2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395\n13\n of \n14\n\n2026, 15:\n10.3390/jcm15187238\n50\n. \nWang ST, Johnson SJ, Mitchell D, Soliman AM, Vora JB, Agarwal SK: \nCost-effectiveness of elagolix versus\nleuprolide acetate for treating moderate-to-severe endometriosis pain in the USA\n. J Comp Eff Res. 2019,\n8:337-55. \n10.2217/cer-2018-0124\n51\n. \nLiu T, Cai Y, Li M, et al.: \nGonadotropin-releasing hormone antagonists versus agonists for endometriosis: a\nsystematic review and meta-analysis of randomized controlled trials\n. Front Endocrinol (Lausanne). 2026,\n17:1979544. \n10.3389/fendo.2026.1979544\n52\n. \nMiller CE, Kim JH, Kroll R, et al.: \nEfficacy, tolerability, and bone density outcomes of elagolix with add-back\ntherapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial\n. Am J\nObstet Gynecol. 2024, 231:630.e1-630.e13. \n10.1016/j.ajog.2024.06.040\n53\n. \nORILISSA patient counseling aid\n. (2026). Accessed: August 7, 2026:\nhttps://www.orilissa.com/hcp/endometriosis-specialist-resources/patient-counseling\n.\n54\n. \nLa Torre F, Vannuccini S, Toscano F, Gallucci E, Orlandi G, Manzi V, Petraglia F: \nLong-term treatment for\nendometriosis with dienogest: efficacy, side effects and tolerability\n. Gynecol Endocrinol. 2024, 40:2336121.\n10.1080/09513590.2024.2336121\n55\n. \nNirgianakis K, Vaineau C, Agliati L, McKinnon B, Gasparri ML, Mueller MD: \nRisk factors for non-response\nand discontinuation of dienogest in endometriosis patients: a cohort study\n. Acta Obstet Gynecol Scand.\n2021, 100:30-40. \n10.1111/aogs.13969\n \n2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395\n14\n of \n14","source_license":"CC0","license_restricted":false}